AMANDA KEENAN: Open Payments
NPI 1124798053 · LEBANON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$993 in 45 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $289 · 2025 $993
Food & beverage: $993
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $261 |
| Madrigal Pharmaceuticals | 6 | $159 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $139 |
| Janssen Biotech, Inc. | 4 | $93 |
| Celltrion USA Inc. | 2 | $75 |
| Lilly USA, LLC | 3 | $71 |
| GlaxoSmithKline, LLC. | 2 | $56 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| PFIZER INC. | 2 | $29 |
| Ardelyx, Inc. | 1 | $26 |
Products named: REZDIFFRA, RINVOQ, TREMFYA, ENTYVIO, MAVYRET, OMVOH, TRELEGY ELLIPTA, ZYMFENTRA.
Industry payments across PA — which companies pay providers there.
